IGF-1 LR3

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified 83-amino-acid analog of human IGF-1. The native IGF-1 molecule (70 amino acids) is the primary downstream mediator of growth hormone's anabolic effects, but its utility as a research compound is limited by its extremely short half-life (12-15 minutes) due to rapid binding by six IGF-binding proteins (IGFBPs). IGF-1 LR3 addresses this limitation through two modifications: an arginine substitution at position 3 (replacing glutamic acid) and a 13-amino-acid N-terminal extension peptide. These changes reduce IGFBP binding affinity by over 100-fold, extending the effective half-life to approximately 20-30 hours and dramatically increasing the fraction of free, bioactive IGF-1 in circulation.

IGF-1 LR3 activates the IGF-1 receptor (IGF-1R), a transmembrane tyrosine kinase receptor that signals through the PI3K-Akt and Ras-MAPK pathways. These are the primary intracellular cascades governing cell proliferation, differentiation, and survival. The critical distinction between IGF-1 LR3 and GH-releasing peptides is the difference between hypertrophy and hyperplasia. GH and standard IGF-1 primarily promote hypertrophy — the enlargement of existing cells. IGF-1 LR3, at sufficient concentrations, can promote hyperplasia — the division and creation of entirely new cells, including satellite cell proliferation in skeletal muscle tissue. This means IGF-1 LR3 has the theoretical capacity to increase the total number of muscle fibers, not merely their size.

Research documents IGF-1 LR3's potent anabolic, anti-catabolic, and cell-proliferative effects. Studies demonstrate enhanced protein synthesis, reduced protein degradation, increased satellite cell activation and differentiation, accelerated recovery from muscle damage, and improved nitrogen retention. The compound also demonstrates insulin-mimetic effects — it can lower blood glucose by promoting glucose uptake into muscle and fat tissue — which researchers must account for in protocol design.

IGF-1 LR3 is suited for advanced researchers investigating muscle hyperplasia, satellite cell biology, anabolic signaling beyond the GH axis, and recovery optimization. It is not a beginner compound — its potent metabolic effects (particularly hypoglycemia risk) and non-GH-axis mechanism require experienced protocol design.

Reconstitute the 1mg vial with 1ml bacteriostatic water (yielding 1mg/ml or 1000mcg/ml). Administer via subcutaneous or intramuscular injection, typically 20-50mcg per day. Due to its insulin-mimetic properties, administer with or shortly after a meal containing carbohydrates to mitigate hypoglycemia risk. The 20-30 hour half-life supports once-daily dosing. Protocols typically run 4-6 weeks on, 4 weeks off to prevent receptor downregulation. Store at 2-8C after reconstitution, -20C for long-term lyophilized storage. IGF-1 LR3 is sensitive to agitation — do not shake the vial.